

Title (en)  
COMPOSITIONS AND METHODS OF USE OF IMMUNOTOXINS COMPRISING RANPIRNASE (RAP) SHOW POTENT CYTOTOXIC ACTIVITY

Title (de)  
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG VON IMMUNTOXINEN MIT RANPIRNASE (RAP) MIT HOHER ZYTOTOXISCHER AKTIVITÄT

Title (fr)  
COMPOSITIONS ET PROCÉDÉS D'UTILISATION D'IMMUNOTOXINES COMPRENANT LA RANPIRNASE (RAP) À PUISSANTE ACTIVITÉ CYTOTOXIQUE

Publication  
**EP 2473187 A1 20120711 (EN)**

Application  
**EP 10812707 A 20100830**

Priority

- US 23847309 P 20090831
- US 26630509 P 20091203
- US 64414609 A 20091222
- US 31699610 P 20100324
- US 73178110 A 20100325
- US 75264910 A 20100401
- US 75414010 A 20100405
- US 75474010 A 20100406
- US 32396010 P 20100414
- US 2010047132 W 20100830

Abstract (en)  
[origin: WO2011026026A1] The present invention concerns methods and compositions for forming immunotoxin complexes having a high efficacy and low systemic toxicity. In preferred embodiments, the toxin moiety is a ranpirnase (Rap), such as Rap(Q). In more preferred embodiments, the immunotoxin is made using dock-and-lock (DNL) technology. The immunotoxin exhibits improved pharmacokinetics, with a longer serum half-life and significantly greater efficacy compared to toxin alone, antibody alone, unconjugated toxin plus antibody or even other types of toxin-antibody constructs. In a most preferred embodiment the construct comprises an anti-Trop-2 antibody conjugated to Rap, although other combinations of antibodies, antibody fragments and toxins may be used to form the subject immunotoxins. The immunotoxins are of use to treat a variety of diseases, such as cancer, autoimmune disease or immune dysfunction.

IPC 8 full level  
**A61K 39/00** (2006.01)

CPC (source: EP)  
**A61K 47/6815** (2017.07); **A61K 47/6849** (2017.07); **A61K 47/6851** (2017.07); **A61P 1/04** (2017.12); **A61P 1/16** (2017.12); **A61P 3/10** (2017.12); **A61P 7/04** (2017.12); **A61P 7/06** (2017.12); **A61P 9/00** (2017.12); **A61P 13/12** (2017.12); **A61P 17/02** (2017.12); **A61P 17/06** (2017.12); **A61P 19/02** (2017.12); **A61P 21/02** (2017.12); **A61P 21/04** (2017.12); **A61P 25/00** (2017.12); **A61P 25/14** (2017.12); **A61P 29/00** (2017.12); **A61P 35/00** (2017.12); **A61P 35/02** (2017.12); **A61P 37/02** (2017.12); **A61P 37/06** (2017.12); **C07K 16/2803** (2013.01); **C07K 16/2887** (2013.01); **C07K 16/30** (2013.01); **A61K 38/00** (2013.01); **C07K 2317/24** (2013.01); **C07K 2317/35** (2013.01); **C07K 2317/77** (2013.01); **C07K 2317/92** (2013.01)

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DOCDB simple family (publication)  
**WO 2011026026 A1 20110303**; AU 2010286496 A1 20120216; BR 112012004274 A2 20161116; CA 2770351 A1 20110303; CA 2770351 C 20190423; CN 102596235 A 20120718; EP 2473187 A1 20120711; EP 2473187 A4 20150916; IN 1662DEN2012 A 20150605; JP 2013503200 A 20130131; JP 6114936 B2 20170419

DOCDB simple family (application)  
**US 2010047132 W 20100830**; AU 2010286496 A 20100830; BR 112012004274 A 20100830; CA 2770351 A 20100830; CN 201080038614 A 20100830; EP 10812707 A 20100830; IN 1662DEN2012 A 20120223; JP 2012527065 A 20100830